Jorge C. Escalante, from the University of Georgia, Athens department of microbiology, and his research team recently received a 5-year, $2.1 million MERIT award extension from the NIH to continue their research into the synthesis of B-12.
Escalante explained that "our coenzyme B-12 work benefits from important collaborations with structural biologists and spectroscopists. Such collaborations allow us to look in detail, from a biophysical and structural standpoint, into how the proteins involved in the assembly of B-12 work. We are trying to learn how the organisms synthesize this very complex molecule, which is the focus of the grant."
Researchers in the lab, both at the graduate and undergraduate levels, analyze the biosynthesis of B-12 in microorganisms through genetic, molecular biological and biochemical methods. Since the genes necessary to encode proteins in B-12 are not found in the human genome, Escalante believes that the biosynthesis of B-12 has potential to be used for future drug delivery and treatments.
"B-12 biosynthetic enzymes represent potential therapeutic targets. The development of antimicrobials that block B-12 biosynthesis in human pathogens is attractive because of the predicted absence of side effects on human cell function. The more we understand how B-12 biosynthetic enzymes work, the better positioned we are for drug development innovations," said Escalante.
With more than $45.8 million in active NIH funding from the 2015 fiscal year, the University of Georgia, Athens is a fruitful life science marketplace. Currently funded research being conducted in Athens include:
To learn more about participating in the 17th Annual BioResearch Product Faire™ Event at UGA on March 30th, 2015, visit the link below.
While in Georgia, make the most of your time and budget by participating in the Emory University event in Atlanta the following day, on March 31, 2016. Learn more about the 17th Annual BioResearch Product Faire Event at Emory here.